U.S. Software Stock News

In early December 2025, Pacsun announced it had teamed up with Affirm to offer interest-free installment payment options and a limited-time 10% "AFFIRM" promo on its Holiday Gift Guide, adding another retail name to Affirm’s nearly 420,000-merchant network. This combination of a fresh Pacsun partnership and recent analyst commentary spotlighting Affirm’s 0% APR loans, Affirm Card, and international expansion underscores how the company is weaving its services more deeply into both online and...

Earlier this month, Bio-Rad Laboratories participated in the Antibody Engineering & Therapeutics conference in San Diego, where Technical Sales Specialist Birthe Jessen-Park presented on the company’s capabilities. At the same time, industry reports profiling Bio-Rad as a key player in the expanding blood collection and diagnostics markets underline how automation, advanced materials, and regulatory-focused solutions are shaping its position in these growing segments. We’ll now examine how...

nVent Electric was recently recognized as one of the “10 Data Center Cooling Companies to Invest In,” as management, at the past 2025 Goldman Sachs Industrials and Materials Conference, outlined plans to reposition the business around modular cooling and power solutions for AI-driven data centers. This shift toward becoming a focused data center infrastructure provider, with an emphasis on liquid cooling technologies, signals a meaningful evolution in how nVent aims to participate in...

S&P Global Ratings recently revised its outlook on LXP Industrial Trust to positive from stable after the REIT sold vacant development projects, used the proceeds to repay debt, and fully leased another development expected to support EBITDA. This outlook shift highlights how LXP’s capital recycling and focus on higher-quality industrial assets are reshaping its balance sheet and earnings profile. We’ll now explore how S&P’s positive outlook, driven by LXP’s deleveraging progress, may...

Recently, analysts upgraded Airbnb to Buy on the back of rebounding bookings, stronger free cash flow, and an increasingly attractive valuation profile. The upgrade underscores how Airbnb’s expanding services, product improvements, and share repurchases are shaping perceptions of its long-term business momentum. We’ll now explore how this upgrade, anchored in bookings strength and free cash flow improvement, may influence Airbnb’s existing investment narrative. We've found 13 US stocks that...

In December 2025, Vital Farms, Inc. (NasdaqGM: VITL) was added to the S&P 1000, S&P 600, S&P 600 Consumer Staples, and the S&P Composite 1500 indices, marking a significant expansion of its presence in key U.S. equity benchmarks. This broad index inclusion could meaningfully increase the stock’s visibility and ownership among institutional and passive investors, potentially reinforcing the company’s position within the consumer staples universe. We’ll now explore how Vital Farms’ broad S&P...

In recent days, research analysts at Wall Street Zen upgraded Innospec from a “hold” to a “buy” rating, while insider Leslie J. Parrette increased their stake and institutional investors adjusted their positions in the specialty chemicals group. Taken together, the analyst upgrade, insider share purchase, and shifting institutional ownership point to rising investor confidence in Innospec’s long-term prospects. With this backdrop of an analyst upgrade and insider buying, we’ll now examine...

Earlier in December 2025, Stoke Therapeutics and Biogen presented long-term clinical data at the American Epilepsy Society meeting showing that investigational antisense oligonucleotide zorevunersen produced durable seizure reductions and improvements in cognition, behavior, and quality of life for Dravet syndrome patients on top of standard anti-seizure medicines. The new propensity score weighted comparison with a natural history cohort, alongside EEG findings and multiple regulatory...

Strategic Education (STRA) has been grinding through a mixed stretch, with the share price down over the past year even as revenue and net income continue to grow. That gap is where things get interesting. See our latest analysis for Strategic Education. At around $80.77, the stock has bounced modestly in the past week, but the year to date share price return remains clearly negative. This suggests that despite steady fundamental progress, sentiment and risk perception are still catching up...

Cardinal Health (CAH) has quietly pulled back about 4% over the past month even after a strong run this year, creating an interesting setup for investors weighing whether the longer term uptrend still holds. See our latest analysis for Cardinal Health. That pullback comes after a powerful run, with the share price still around $198.18 and a strong year to date share price return feeding into an impressive multi year total shareholder return. This suggests momentum is cooling, but the broader...

PACCAR Inc recently announced executive promotions effective January 1, 2026, including elevating Kevin D. Baney to President and expanding John N. Rich’s remit as Executive Vice President and Chief Technology Officer, alongside leadership adjustments for PACCAR Parts, Peterbilt, Kenworth, and Dynacraft. The Board also declared an extra US$1.40 per share cash dividend payable in early 2026 and reaffirmed its regular US$0.33 quarterly dividend, underscoring how capital returns and leadership...

In Q3 fiscal 2025, Domino's Pizza reported revenue of US$1.15 billion, a 6.2% year-over-year increase, alongside earnings per share that exceeded analyst estimates and net additions of 29 U.S. stores, reinforcing its footprint of more than 21,000 locations worldwide. Management’s expectation for more than 175 net new U.S. stores in fiscal 2025, combined with ongoing international expansion, highlights Domino’s focus on scaling its delivery-led model despite softer category traffic. We’ll now...

Vaxcyte, Inc. recently began dosing participants in its pivotal OPUS Phase 3 noninferiority trial of VAX-31, a 31-valent pneumococcal conjugate vaccine for adults, designed in alignment with the U.S. Food and Drug Administration and intended to support a future Biologics License Application. The study’s direct head-to-head comparisons versus both Capvaxive (PCV21) and Prevnar 20 (PCV20), with ambitious noninferiority and superiority immunogenicity goals, position VAX-31 as a potential...

Morgan Stanley’s downgrade of HCA Healthcare (HCA) to Underweight, paired with L1 Capital trimming its stake after strong gains, has investors rethinking whether the recent run up justifies today’s valuation. See our latest analysis for HCA Healthcare. Those concerns are landing after a huge run, with HCA’s share price at $484.77 and a powerful year to date share price return of 62.81%. Its five year total shareholder return of 209.92% signals long term momentum that may now be cooling at the...

Earlier this quarter, Advanced Energy Industries reported Q3 results with revenue rising 23.8% year on year and both revenue and EBITDA surpassing analyst estimates, alongside issuing next-quarter EPS guidance that also came in ahead of forecasts. Analysts have since raised their earnings estimates without any cuts, reinforcing a strong consensus that the company’s earnings trajectory may be improving. Next, we’ll explore how Advanced Energy’s earnings beat and upgraded guidance might...

Structure Therapeutics (GPCR) has just delivered striking Phase 2b data for its oral GLP 1 candidate aleniglipron in obesity, and the stock has been trading as if investors have noticed. See our latest analysis for Structure Therapeutics. Those Phase 2b wins and the follow on offering have clearly reset expectations, with Structure Therapeutics’ share price return up triple digits over the past quarter and year to date. This signals powerful momentum at the current 67.06 dollars level. If...

L1 Capital International Fund has recently exited its long-term position in Eagle Materials Inc., citing concerns that a softer U.S. housing cycle and housing affordability pressures could weigh on demand and pricing for key products such as wallboard and cement. This complete divestment by a previously significant shareholder highlights how worries about new housing starts and construction activity are influencing institutional views on building materials exposure. We’ll now examine how L1...

ADMA Biologics recently reported quarterly results that beat revenue expectations, raised its 2025 and 2026 earnings guidance, and highlighted an FDA‑approved manufacturing process expected to lift yields by around 20% and support long‑term margin expansion. This combination of stronger near‑term performance and structurally improved manufacturing efficiency underpins management’s projection that earnings per share could be around four times higher by 2030. Next, we’ll examine how the new...

Sabine Royalty Trust recently reported December 2025 preliminary production of about 28,904 barrels of oil and 796,698 Mcf of gas, alongside a monthly cash distribution of US$0.196670 per unit payable on December 29, 2025, to holders of record on December 15, 2025. This payout represents the fourth straight monthly reduction and the lowest distribution since 2021, underscoring how weaker production has compressed income for unitholders. Against this backdrop of lower production and a sharply...

Earlier this year, QuidelOrtho reported third-quarter results that exceeded analyst expectations on both revenue and earnings and raised its full-year guidance, despite posting the slowest revenue growth among major medical device and diagnostics peers. The combination of an earnings and revenue beat with a guidance increase, even amid relatively modest growth, highlights how execution and outlook can matter as much as headline growth rates for a diagnostics company formed from the Quidel...

SL Green Realty (SLG) just reported 2.3 million square feet of Manhattan office leases signed in 2025, plus a 1.2 million square foot pipeline, putting its same store occupancy target of 93% within sight. See our latest analysis for SL Green Realty. Even with this leasing momentum and a latest share price of $44.64, the 7 day share price return of 7.49% comes after a much steeper 90 day share price decline of 32.02%. At the same time, the 3 year total shareholder return of 66.77% shows that...

Kymera Therapeutics recently reported positive Phase 1b data for KT-621, its first-in-class oral STAT6 degrader in moderate to severe atopic dermatitis, and subsequently secured FDA Fast Track designation for KT-621, while also completing an upsized US$602.0 million follow-on equity offering. Together, the encouraging KT-621 efficacy and safety signals, regulatory acceleration via Fast Track, and strengthened cash position could meaningfully reshape expectations for Kymera’s Type 2...

Analyst reaction to Arch Capital Group (ACGL) after its mixed Q3 results is shaping the conversation, with softer written premium growth and cooling mortgage and reinsurance demand now front and center for investors. See our latest analysis for Arch Capital Group. At around $93.92 per share, Arch’s recent 7.48% 3 month share price return contrasts with a more modest 2.82% 1 year total shareholder return. This hints that near term optimism is building even as conference appearances and mixed...

Key Insights Scinai Immunotherapeutics to hold its Annual General Meeting on 22nd of December Total pay for CEO Amir...